418 results about "Carrier protein" patented technology

The technology described herein relates to novel CRISPR / Cas systems and components thereof, vectors, proteins, fusion proteins, ribonucleoprotein complexes and methods of using the novel systems and components. The new system can be used in CRIS PRi applications and can be fused with any number of effector domain patterns, such as nuclease, base editor, leader editor, and the like, to conduct a variety of DNA modifications.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The present disclosure provides lysosomal targeting bifunctional molecules that target disease causing anti-MuSK autoantibodies for degradation. The lysosomal targeting bifunctional molecules include a ligand moiety that specifically binds to an asialoglycoprotein receptor (ASGPR), and which is linked via a carrier protein to a muscle-specific kinase (MuSK) polypeptide that specifically binds target anti-MuSK autoantibodies.

Disclosed are an artificial hapten and artificial antigen of fentanyl, and a preparation method and application thereof. The artificial hapten of fentanyl according to the invention has an active group capable of being coupled with a carrier protein, and can be used as an antigenic determinant; and the artificial antigen of fentanyl further prepared can be immunized to obtain an anti-fentanyl antibody with high affinity, high sensitivity and strong specificity, and the antigen-antibody can be used in enzyme-linked immunity, immunochromatography and other technologies.

The invention discloses a test strip for detecting etoxazole and application of the test strip. The test strip comprises a sample absorption pad (1), a conjugate release pad (2), a reaction film (3), a water absorption pad (4) and a bottom plate (7), the reaction film is provided with a detection line (5) coated with an etoxazole hapten-carrier protein conjugate and a quality control line (6) coated with a goat anti-mouse antibody, and the conjugate release pad (2) is sprayed with an etoxazole monoclonal antibody-colloidal gold marker. The invention also provides a method for detecting residual etoxazole in vegetables and fruits by using the etoxazole test strip. The test strip provided by the invention has the characteristics of simplicity in operation, high sensitivity, high detection speed, low cost and the like, and is suitable for screening and on-site monitoring of a large number of samples.

The invention discloses a preparation method of collagen nano polymer particles, which comprises the following steps: carrying out surface hydrolysis on organized collagen to prepare a microsphere base material; the preparation method comprises the following steps: uniformly mixing a microsphere base material, a target load, a nonionic surfactant and polyol ester in proportion to prepare a microsphere modified base material; and uniformly mixing the microsphere modified base material, an ether compound and a chemical auxiliary agent according to a ratio to prepare collagen microspheres, namely the collagen nano polymer particles. The preparation method comprises the following steps: firstly, reducing the volume of collagen through enzyme hydrolysis, reducing biological stimulation possibly caused by drug loading, and strengthening the drug loading property of the collagen nano polymer; and secondly, a polymer crystal region appears in the carrier protein in an aqueous solution by utilizing subsequent surface modification, so that the drug carrier can control the release progress of the loaded drug, and the drug carrier can permeate into deep tissues through the surface layer of the skin.

The invention provides a safrole hapten and application of the safrole hapten in detection of safrole through immunoassay. The structure of the safrole hapten is shown in the specification. The two safrole haptens provided by the invention have spacer arms with proper lengths, and after the safrole haptens are coupled with carrier protein, the haptens can be fully exposed, and recognition of the spacer arms can be avoided as much as possible. The safrole hapten is used for preparing an artificial antigen and an antibody, and the obtained safrole monoclonal antibody is high in titer, strong in specificity and high in affinity. An immunoassay method constructed on the basis of the safrole artificial antigen and antibody has high specificity and sensitivity, the lowest detection limit LOD is 0.09 ng / mL, the half inhibitory concentration IC50 is 2.05 ng / mL, the quantitative detection range is 0.28-14.89 ng / mL, no cross reaction exists on safrole analogues, and rapid qualitative and quantitative detection can be conducted on safrole in a sample.

The present invention relates to the field of biomedicine, and particularly to an assembled protein nanocarrier CABRi for targeted delivery of small interfering nucleic acids, its preparation method and application. The assembled protein nanocarrier CABRi (CABRi series of siRNA protein delivery carriers) designed by the present invention can efficiently load siRNA without sequence selectivity, and can be mixed with one or more siRNAs in a certain ratio to form a carrier / small nucleic acid complex CABRi-siRNA, which self-assembles into a nanoparticle with a size of 10-100 nm. The present invention constructs a brand-new siRNA delivery carrier, breaking through three key technical bottlenecks in siRNA drug delivery, namely, extremely low in vivo delivery efficiency of siRNA, endosomal escape and extrahepatic delivery problems, and finally achieving the purposes of efficient delivery, endosomal escape, targeting extrahepatic organs or tumors, high safety and easy industrialization of siRNA drugs.

The present disclosure provides lysosomal targeting bifunctional molecules that target disease causing anti-TSHR autoantibodies for degradation. The lysosomal targeting bifunctional molecules include a ligand moiety that specifically binds to an asialoglycoprotein receptor (ASGPR), and which is linked via a carrier protein to a thyroid stimulating hormone receptor (TSHR) polypeptide that specifically binds target anti-TSHR autoantibodies.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

The invention discloses a phthalimidic acid hapten, an artificial antigen, an antibody, and a preparation method and application of the phthalimidic acid hapten and the artificial antigen. The structure of the phthalimide acid hapten is shown as a formula (I), and the phthalimide acid hapten is obtained by introducing a carboxyl active group with a spacer arm with a certain length to carboxyl of phthalimide acid, so that the phthalimide acid hapten can be coupled with carrier protein to obtain an artificial antigen for immunization; the phthalimide hapten retains all characteristic groups of the phthalimide, the original structural characteristics of the phthalimide are changed to the minimum extent, and a foundation is laid for generating an antibody with higher specificity and higher sensitivity for subsequently stimulating animal immune response. An artificial antigen and a phthalimide acid monoclonal antibody are prepared through the hapten, indirect competitive ELISA based on the monoclonal antibody has the lowest detection limit of phthalimide acid of 2.44 ng / mL, IC50 of 17.29 ng / mL and the linear range of 5.02-59.51 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention discloses a method for improving the water-retaining property of meat paste, which specifically comprises the following steps: firstly, sufficiently tumbling and chopping fresh meat paste to be treated at low temperature, and adjusting the pH value of the meat paste to be neutral; then, protein-phospholipid composite emulsion is added into the meat paste, the protein-phospholipid composite emulsion is prepared by mixing phospholipid extracted from livestock and poultry head tissues, a carrier protein solution and algal polysaccharides, then mixing the mixture with edible oil, performing ultrasonic treatment, emulsifying and homogenizing, and finally, a small amount of the protein-phospholipid composite emulsion is added into the pretreated meat paste for many times, and homogenizing at high pressure, adding transglutaminase, and packaging in vacuum. The method is simple, the steps are easy to operate, the pH value of the meat paste can be reduced, the loss rate of juice in the meat paste can be reduced, the water-retaining property of the meat paste can be improved, and meanwhile, the structural stability of the meat paste can be enhanced by improving the combination of fat and water.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The invention relates to the field of biological medicine, in particular to an assembled protein nano-carrier CABRi for targeted delivery of small interfering nucleic acid as well as a preparation method and application of the assembled protein nano-carrier CABRi. The assembled protein nano-carrier CABRi (siRNA protein delivery carrier CABRi series) designed by the invention can efficiently load siRNA without sequence selectivity, and can be mixed with one or more siRNAs according to a certain proportion to form a carrier / small nucleic acid compound CABRi-siRNA, and the carrier / small nucleic acid compound CABRi-siRNA is self-assembled into a nano particle with the size of 10-100nm. The invention constructs a brand new siRNA delivery carrier, breaks through three key technical bottlenecks in siRNA drug delivery, namely the problems of extremely low siRNA in-vivo delivery efficiency, endosome escape and extrahepatic delivery, and finally achieves the purposes of efficient delivery, endosome escape, targeting of extrahepatic organs or tumors, high safety and easy industrialization of siRNA drugs.

The invention belongs to the technical field of biochemical engineering, and particularly relates to a nitrazene substance artificial hapten, an artificial antigen and a preparation method and application of the nitrazene substance artificial hapten and the artificial antigen. The artificial hapten of the nitrazene substance retains the characteristic structure of the nitrazene substance to the greatest extent, has an active group capable of being coupled with carrier protein, and can be used as an antigenic determinant; the further prepared artificial antigen of the nitrazene substance can be used for immunizing to obtain an anti-nitrazene substance antibody with high affinity, high sensitivity and strong specificity, and a polyclonal antibody obtained by immunizing a New Zealand white rabbit can be used for carrying out rapid and accurate immunodetection and immunoassay on the nitrazene substance.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to carrier proteins. These methods are serotype specific and include acid hydrolysis, the addition of sodium chloride to the reductive amination reaction, and the addition of sucrose to solubilize the polysaccharide. The polysaccharide-protein conjugates prepared using the methods of the present invention can be included in a multivalent pneumococcal conjugate vaccine.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

The present invention relates to a recombinant organism or microorganism having a decreased pool of crotonic acid compared to the organism or microorganism from which it is derived due to at least one of: (i) an increased conversion of crotonyl-CoA into butyryl-CoA; and / or an increased conversion of butyryl-CoA into butyric acid; (ii) an increased conversion of crotonyl-CoA into 3-hydroxybutyryl-CoA; and / or an increased conversion of 3-hydroxybutyryl-CoA into 3-hydroxybutyric acid; (iii) an increased conversion of crotonic acid into crotonyl-CoA; (iv) an increased conversion of crotonyl-[acyl-carrier protein] into butyryl [acyl-carrier-protein]; (v) a decreased conversion of crotonyl-CoA into crotonic acid; and / or (vi) a decreased conversion of crotonyl-[acyl-carrier protein] into crotonic acid. Moreover, the present invention relates to the use of such a recombinant organism or microorganism for the production of alkenes with the enzyme ferulic acid decarboxylase. Further, the present invention relates to a method for the production of isobutene or butadiene by culturing such a recombinant organism or microorganism in a suitable culture medium under suitable conditions.

Disclosed herein are immune activating conjugates with immunogenic carrier proteins coupled to hapten and immune cell receptor agonist-containing polymers. The polymers promote uptake by B cells, enabling intracellular immune cell receptor activation and formation of long-lived antibody-secreting cells. In some aspects, disclosed herein in is a conjugate comprising an immunogenic carrier protein coupled to a polymer, wherein the polymer includes: i) a first monomeric unit comprising a first monomer coupled to a hapten, and ii) a second monomeric unit comprising a second monomer coupled to an immune cell receptor agonist.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

The invention discloses a carrier protein with an adjuvant function and application thereof. The carrier protein with the adjuvant function has a sequence as shown in SEQ ID NO. 1. According to the carrier protein with the adjuvant function, a part of sequence is intercepted from the flagellin FliC of Burkholderia cepacia, so that the adjuvant activity of the flagellin is reserved, and the immunogenicity and antigenicity of the flagellin are reduced; when being applied to a fusion protein or a small-molecule drug, the fusion protein or the small-molecule drug can enhance the immunogenicity, so that the fusion protein or the small-molecule drug has important significance on subunit vaccines, polypeptide vaccines or small-molecule drug carriers.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The present invention discloses a method for increasing the yield of maize. The method is to overexpress an auxin influx carrier protein in maize, screen for transformed plants with significantly increased ear row number, grain weight per ear, or test weight, and increase the yield of maize. Overexpression of the auxin transport protein in the present invention can significantly increase the test weight and ear row number of maize kernels in inbred lines and hybrids, thereby significantly increasing the yield. Under the same genetic background, both the test weight and ear row number of kernels are positively correlated with the yield of maize. Selecting transgenic maize into which the auxin transport protein gene has been introduced using the test weight and ear row number can effectively obtain high-yield transgenic maize.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and / or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The invention discloses a specific antibody for detecting cathepsin S, a kit and application. The specific antibody for detecting cathepsin S is prepared by coupling a cathepsin S specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The specific antibody for detecting cathepsin S can specifically detect cathepsin S, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or curative effect evaluation of the chronic obstructive pulmonary disease, the marker has good diagnosis sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of the chronic obstructive pulmonary disease, and is worthy of popularization and application. The method has important significance and clinical application value for diagnosis and treatment of chronic obstructive pulmonary diseases.